VEGF is key to the process of angiogenesis in retinal neovascularization during PDR and VEGF antagonists are widely administered for the therapy of ocular pathologies including PDR, age-related macular degeneration, retinal vessel occlusion, and diabetic macular edema [42]. Here, VEGFA is linked to diabetic macular edema.